Press Room

Press Clipping / Sep 23, 2020

Hovione to support production of antiviral Veklury for COVID-19

Manufacturing Chemist, September 23, 2020

Hovione has signed a partnership agreement with Ligand to significantly ramp up the production output of Captisol

Captisol, a Ligand product, is a chemically modified cyclodextrin proven to improve the solubility and stability of drugs.

It is used in the formulation of Gilead’s Covid-19 treatment Veklury (remdesivir). Hovione is the sole producer of this key enabling excipient.

The COVID-19 pandemic has, to date, killed one million people; studies show that in the next 3 months cumulative deaths may more than double.

“To meet Captisol demand associated with Veklury, Hovione will soon be producing per month the quantity it usually produces in one year. This sudden spike in demand has required unique mobilisation efforts across the Hovione network to secure additional raw material supply, execute major capital expenditure projects at our sites, maximise operational efficiency, hire additional talent and identify external partners to expand our overall capacity."

"The pharmaceutical supply chain is working together in an unprecedented fashion to treat patients and save lives. Hovione is privileged to be part of this truly global response,” said Jean-Luc Herbeaux, Chief Operating Officer.

“Ligand values its longstanding partnership with Hovione,” said Matt Foehr, President and Chief Operating Officer of Ligand.

“Their excellent customer service, global commitment to quality and high pharmaceutical standards make them an ideal partner for Captisol, a critical component for a number of life-saving medicines."

"We commend them for responsibly and efficiently partnering with Ligand to manage the scale up and expansion of their operations to contribute to global health during the pandemic.”

 

Read the article on Manufacturing Chemist website

 

Also in the Press Room

See All

In an interview with Executiva, a portuguese media outlet focused on women´s leadership, Diane Villax, co-founder and long-standing leader of Hovione, reflects on her journey and the company’s development over more than six decades. Diane Villax’s career began at a time when few women worked outside the home. At 19, she joined a trading company as a foreign languages correspondent, where she developed essential business skills — including commercial correspondence, banking and export procedures — that later proved instrumental in helping her husband, Ivan Villax, establish Hovione in 1959. From its earliest days operating in the family home in Lisbon, Hovione adopted an international outlook. The company’s first major customers were in Japan, setting demanding quality standards that helped shape its long-term position in global markets. Over the following decades, Hovione expanded its footprint with the construction of its first manufacturing site in Loures (1969), followed by expansion to Macau (1986), the United States (New Jersey, early 2000s) and Ireland (Cork). The company grew into a global organization with more than 2,500 employees — including over 300 scientists — and a reputation as a preferred supplier to leading pharmaceutical companies worldwide. Throughout the interview, Diane highlights the values that have guided the company’s development: a commitment to excellence, a strong work ethic, and a focus on quality and long-term relationships. Although she did not have formal business training, she learned “on the job” and brought discipline, precision and structure to her role — particularly in the company’s early financial and administrative leadership. Now in her nineties and an active member of Hovione’s Board of Directors, Diane Villax remains engaged with the company’s evolution and governance, reflecting a continued commitment to its long-term development. Her story reflects entrepreneurial drive, resilience and long-term leadership — and offers insight into the values that have shaped Hovione’s trajectory for more than six decades. Read the full interview at Executiva.pt (in portuguese).    

Article

Hovione’s Diane Villax: “I was not brought up to be a business woman”

Feb 23, 2026